secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001641172-25-021356
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA reports preclinical data: topical Ketamir-2 comparable to injected morphine in pain model
--------------------------------------------------------------------------------

- Topical Ketamir-2 nearly eliminated paw licking and markedly reduced paw lifting in both acute (0-10 min) and inflammatory (15-60 min) phases.
- Comparable efficacy to injected morphine across both pain phases; effects consistent across all 5-min intervals.
- Company continues Phase 1 oral Ketamir-2 trial; Phase 2a in neuropathic pain expected later in 2025.
- Topical Ketamir-2 is being developed as potential non-opioid treatment for diabetic neuropathy, osteoarthritis, and other pain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225021356/0001641172-25-021356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225021356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-021356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer